Publications of Susanne B Haga    :chronological  alphabetical  combined  bibtex listing:

search PubMed.

Journal Articles

  1. Kantor, A; Haga, SB, The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine., Journal of Personalized Medicine, vol. 11 no. 1 (January, 2021) [doi]  [abs].
  2. Haga, SB; Mills, R; Moaddeb, J; Liu, Y; Voora, D, Independent Community Pharmacists' Experience in Offering Pharmacogenetic Testing., Pharmacogenomics and Personalized Medicine, vol. 14 (January, 2021), pp. 877-886 [doi]  [abs].
  3. Haga, SB; Mills, R; Moaddeb, J; Liu, Y; Voora, D, Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting., Pharmacogenomics and Personalized Medicine, vol. 14 (2021), pp. 785-796 [doi]  [abs].
  4. Haga, SB, Individualizing pharmacogenomic test results in the context of the microbiome., Per Med, vol. 17 no. 6 (November, 2020), pp. 459-468 [doi]  [abs].
  5. Brown, L; Eum, S; Haga, SB; Strawn, JR; Zierhut, H, Clinical Utilization of Pharmacogenetics in Psychiatry - Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry., Pharmacopsychiatry, vol. 53 no. 4 (July, 2020), pp. 162-173 [doi]  [abs].
  6. Haga, SB, Toward digital-based interventions for medication adherence and safety., Expert Opin Drug Saf, vol. 19 no. 6 (June, 2020), pp. 735-746 [doi]  [abs].
  7. Haga, SB; Orlando, LA, The enduring importance of family health history in the era of genomic medicine and risk assessment., Per Med, vol. 17 no. 3 (May, 2020), pp. 229-239 [doi]  [abs].
  8. Haga, SB; Shaw, R; Kneifel, C; Bond, SJ; Ginsburg, GS, Promoting Wellness Through Mobile Health Technology in a College Student Population: Protocol Development and Pilot Study., Jmir Research Protocols, vol. 9 no. 4 (April, 2020), pp. e16474 [doi]  [abs].
  9. Phillips, K; Haga, S, Precision Medicine in Primary Care: Bespoke. Genetic and Genomic. And Maybe Not Ready, Managed Care (Langhorne, Pa.), vol. 28 no. 12 (December, 2019), pp. 30-33  [abs].
  10. Haga, SB, Managing Increased Accessibility to Pharmacogenomic Data., Clinical Pharmacology and Therapeutics, vol. 106 no. 5 (November, 2019), pp. 922-924 [doi] .
  11. Weitzel, KW; Duong, BQ; Arwood, MJ; Owusu-Obeng, A; Abul-Husn, NS; Bernhardt, BA; Decker, B; Denny, JC; Dietrich, E; Gums, J; Madden, EB; Pollin, TI; Wu, RR; Haga, SB; Horowitz, CR, A stepwise approach to implementing pharmacogenetic testing in the primary care setting., Pharmacogenomics, vol. 20 no. 15 (October, 2019), pp. 1103-1112 [doi]  [abs].
  12. Haga, SB, First Responder to Genomic Information: A Guide for Primary Care Providers., Mol Diagn Ther, vol. 23 no. 4 (August, 2019), pp. 459-466 [doi]  [abs].
  13. Villegas, C; Haga, SB, Access to Genetic Counselors in the Southern United States., Journal of Personalized Medicine, vol. 9 no. 3 (July, 2019) [doi]  [abs].
  14. Haga, SB; Liu, Y, Patient characteristics, experiences and perceived value of pharmacogenetic testing from a single testing laboratory., Pharmacogenomics, vol. 20 no. 8 (June, 2019), pp. 581-587 [doi]  [abs].
  15. Haga, SB; Moaddeb, J, Pharmacogenomics courses in pharmacy school curricula., Pharmacogenomics, vol. 20 no. 9 (June, 2019), pp. 625-630 [doi]  [abs].
  16. Haga, SB; Kim, E; Myers, RA; Ginsburg, GS, Primary Care Physicians' Knowledge, Attitudes, and Experience with Personal Genetic Testing., Journal of Personalized Medicine, vol. 9 no. 2 (May, 2019) [doi]  [abs].
  17. Wu, RR; Myers, RA; Buchanan, AH; Dimmock, D; Fulda, KG; Haller, IV; Haga, SB; Harry, ML; McCarty, C; Neuner, J; Rakhra-Burris, T; Sperber, N; Voils, CI; Ginsburg, GS; Orlando, LA, Effect of Sociodemographic Factors on Uptake of a Patient-Facing Information Technology Family Health History Risk Assessment Platform., Applied Clinical Informatics, vol. 10 no. 2 (March, 2019), pp. 180-188 [doi]  [abs].
  18. Haga, SB, Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges., Pharmacogenomics and Personalized Medicine, vol. 12 (2019), pp. 273-285 [doi]  [abs].
  19. Madhavan, S; Bullis, E; Myers, R; Zhou, CJ; Cai, EM; Sharma, A; Bhatia, S; Orlando, LA; Haga, SB, Awareness of family health history in a predominantly young adult population., Plos One, vol. 14 no. 10 (2019), pp. e0224283 [doi]  [abs].
  20. Peyser, B; Perry, EP; Singh, K; Gill, RD; Mehan, MR; Haga, SB; Musty, MD; Milazzo, NA; Savard, D; Li, Y-J; Trujilio, G; Voora, D, Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings., Circulation. Genomic and Precision Medicine, vol. 11 no. 9 (September, 2018), pp. e002228 [doi]  [abs].
  21. Haga, SB; Kantor, A, Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing., Health Aff (Millwood), vol. 37 no. 5 (May, 2018), pp. 717-723 [doi]  [abs].
  22. Mills, R; Haga, SB, Qualitative user evaluation of a revised pharmacogenetic educational toolkit., Pharmacogenomics and Personalized Medicine, vol. 11 (2018), pp. 139-146 [doi]  [abs].
  23. Haga, SB; Friedman, B; Richard, G, Considering the Benefits and Risks of Research Participants' Access to Sequence Data., Genet Test Mol Biomarkers, vol. 21 no. 12 (December, 2017), pp. 717-721 [doi]  [abs].
  24. Huddleston, KL; Klein, E; Fuller, A; Jo, G; Lawrence, G; Haga, SB, Introducing personalized health for the family: the experience of a single hospital system., Pharmacogenomics, vol. 18 no. 17 (November, 2017), pp. 1589-1594 [doi]  [abs].
  25. Haga, SB, Informational Quest., Circ Cardiovasc Genet, vol. 10 no. 4 (August, 2017) [doi] .
  26. Haga, SB, Educating patients and providers through comprehensive pharmacogenetic test reports., Pharmacogenomics, vol. 18 no. 11 (July, 2017), pp. 1047-1050 [doi] .
  27. Mills, R; Ensinger, M; Callanan, N; Haga, SB, Development and Initial Assessment of a Patient Education Video about Pharmacogenetics., Journal of Personalized Medicine, vol. 7 no. 2 (May, 2017) [doi]  [abs].
  28. Haga, SB; Mills, R; Moaddeb, J; Allen LaPointe, N; Cho, A; Ginsburg, GS, Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing., Pharmacogenomics, vol. 18 no. 4 (March, 2017), pp. 359-367 [doi]  [abs].
  29. Haga, SB, Update: looking beyond the 100,000 Genome Project., Per Med, vol. 14 no. 2 (March, 2017), pp. 85-87 [doi] .
  30. Haga, SB; Moaddeb, J; Mills, R; Voora, D, Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting., Pharmacogenomics, vol. 18 no. 4 (March, 2017), pp. 327-335 [doi]  [abs].
  31. Haga, SB, Integrating pharmacogenetic testing into primary care., Expert Review of Precision Medicine and Drug Development, vol. 2 no. 6 (2017), pp. 327-336, Informa UK Limited [doi]  [abs].
  32. Singh, K; Peyser, B; Trujillo, G; Milazzo, N; Savard, D; Haga, SB; Musty, M; Voora, D, Rationale and design of the SLCO1B1 genotype guided statin therapy trial., Pharmacogenomics, vol. 17 no. 17 (November, 2016), pp. 1873-1880 [doi] .
  33. Haga, SB; Mills, R; Moaddeb, J; Allen Lapointe, N; Cho, A; Ginsburg, GS, Patient experiences with pharmacogenetic testing in a primary care setting., Pharmacogenomics, vol. 17 no. 15 (October, 2016), pp. 1629-1636 [doi]  [abs].
  34. Haga, SB; Mills, R; Moaddeb, J, Evaluation of a pharmacogenetic educational toolkit for community pharmacists., Pharmacogenomics, vol. 17 no. 14 (September, 2016), pp. 1491-1502 [doi]  [abs].
  35. Haga, SB; Mills, R, A review of consent practices and perspectives for pharmacogenetic testing., Pharmacogenomics, vol. 17 no. 14 (September, 2016), pp. 1595-1605 [doi]  [abs].
  36. Haga, SB, Challenges of development and implementation of point of care pharmacogenetic testing., Expert Rev Mol Diagn, vol. 16 no. 9 (September, 2016), pp. 949-960 [doi]  [abs].
  37. Haga, SB; Solomon, BD, Considerations of pharmacogenetic testing in children., Pharmacogenomics, vol. 17 no. 9 (June, 2016), pp. 975-977 [doi] .
  38. Arora, S; Haverfield, E; Richard, G; Haga, SB; Mills, R, Clinical and Counseling Experiences of Early Adopters of Whole Exome Sequencing., J Genet Couns, vol. 25 no. 2 (April, 2016), pp. 337-343 [doi]  [abs].
  39. Haga, SB; Moaddeb, J, Proposal for a pharmacogenetics certificate program for pharmacists., Pharmacogenomics, vol. 17 no. 6 (April, 2016), pp. 535-539 [doi] .
  40. Haga, SB; Moaddeb, J; Mills, R; Patel, M; Kraus, W; Allen LaPointe, NM, Incorporation of pharmacogenetic testing into medication therapy management., Pharmacogenomics, vol. 16 no. 17 (November, 2015), pp. 1931-1941 [doi]  [abs].
  41. Moaddeb, J; Mills, R; Haga, SB, Community pharmacists' experience with pharmacogenetic testing., J Am Pharm Assoc (2003), vol. 55 no. 6 (November, 2015), pp. 587-594 [doi]  [abs].
  42. Haga, SB; Mills, R; Aucoin, J; Taekman, J, Interprofessional education for personalized medicine through technology-based learning., Per Med, vol. 12 no. 3 (June, 2015), pp. 237-243 [doi]  [abs].
  43. Haga, SB; Allen LaPointe, NM; Moaddeb, J, Challenges to integrating pharmacogenetic testing into medication therapy management., J Manag Care Spec Pharm, vol. 21 no. 4 (April, 2015), pp. 346-352 [doi]  [abs].
  44. Mills, R; Powell, J; Barry, W; Haga, SB, Information-seeking and sharing behavior following genomic testing for diabetes risk., J Genet Couns, vol. 24 no. 1 (February, 2015), pp. 58-66 [doi]  [abs].
  45. Deverka, PA; Haga, SB, Comparative effectiveness research and demonstrating clinical utility for molecular diagnostic tests., Clin Chem, vol. 61 no. 1 (January, 2015), pp. 142-144 [doi] .
  46. Gallagher, P; King, HA; Haga, SB; Orlando, LA; Joy, SV; Trujillo, GM; Scott, WM; Bembe, M; Creighton, DL; Cho, AH; Ginsburg, GS; Vorderstrasse, A, Patient beliefs and behaviors about genomic risk for type 2 diabetes: implications for prevention., J Health Commun, vol. 20 no. 6 (2015), pp. 728-735 [doi]  [abs].
  47. Haga, SB; Mills, R, Nurses' communication of pharmacogenetic test results as part of discharge care., Pharmacogenomics, vol. 16 no. 3 (2015), pp. 251-256 [doi]  [abs].
  48. Haga, SB; Moaddeb, J, Potential use of auxiliary labels to promote patient awareness of pharmacogenetic testing., Pharmacogenomics, vol. 16 no. 4 (2015), pp. 299-301 [doi] .
  49. Haga, SB; Allen LaPointe, NM; Moaddeb, J; Mills, R; Patel, M; Kraus, WE, Pilot study: incorporation of pharmacogenetic testing in medication therapy management services., Pharmacogenomics, vol. 15 no. 14 (November, 2014), pp. 1729-1737 [doi]  [abs].
  50. Haga, SB; Mills, R; Bosworth, H, Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response., Patient Educ Couns, vol. 97 no. 1 (October, 2014), pp. 10-15 [doi]  [abs].
  51. Haga, SB; LaPointe, NMA; Cho, A; Reed, SD; Mills, R; Moaddeb, J; Ginsburg, GS, Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting., Pharmacogenomics, vol. 15 no. 13 (September, 2014), pp. 1677-1686 [doi]  [abs].
  52. Mills, R; Haga, SB, Genomic counseling: next generation counseling., J Genet Couns, vol. 23 no. 4 (August, 2014), pp. 689-692 [24026254], [doi]  [abs].
  53. Mills, R; Barry, W; Haga, SB, Public trust in genomic risk assessment for type 2 diabetes mellitus., J Genet Couns, vol. 23 no. 3 (June, 2014), pp. 401-408 [doi]  [abs].
  54. Li, JH; Joy, SV; Haga, SB; Orlando, LA; Kraus, WE; Ginsburg, GS; Voora, D, Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients., Journal of Personalized Medicine, vol. 4 no. 2 (March, 2014), pp. 147-162 [doi]  [abs].
  55. Haga, SB; Moaddeb, J, Comparison of delivery strategies for pharmacogenetic testing services., Pharmacogenet Genomics, vol. 24 no. 3 (March, 2014), pp. 139-145 [24384556], [doi]  [abs].
  56. Zhao, JQ; Haga, SB, Promoting the participant-researcher partnership., Genet Med, vol. 16 no. 3 (March, 2014), pp. 228-230 [24009003], [doi] .
  57. Haga, SB, Delivering pharmacogenetic testing to the masses: an achievable goal?, Pharmacogenomics, vol. 15 no. 1 (January, 2014), pp. 1-4 [24329184], [doi] .
  58. Haga, SB; Mills, R; Pollak, KI; Rehder, C; Buchanan, AH; Lipkus, IM; Crow, JH; Datto, M, Developing patient-friendly genetic and genomic test reports: formats to promote patient engagement and understanding., Genome Medicine, vol. 6 no. 7 (2014), pp. 58 [doi]  [abs].
  59. Haga, SB; Mills, R; Moaddeb, J, Pharmacogenetic information for patients on drug labels., Pharmacogenomics and Personalized Medicine, vol. 7 (2014), pp. 297-305 [doi]  [abs].
  60. Haga, SB; Barry, WT; Mills, R; Svetkey, L; Suchindran, S; Willard, HF; Ginsburg, GS, Impact of delivery models on understanding genomic risk for type 2 diabetes., Public Health Genomics, vol. 17 no. 2 (2014), pp. 95-104 [doi]  [abs].
  61. Haga, SB; LaPointe, NMA, The potential impact of pharmacogenetic testing on medication adherence., Pharmacogenomics J, vol. 13 no. 6 (December, 2013), pp. 481-483 [23999596], [doi]  [abs].
  62. Haga, SB, 100k Genome Project: sequencing and much more., Per Med, vol. 10 no. 8 (November, 2013), pp. 761-764 [doi] .
  63. Clayton, EW; Haga, S; Kuszler, P; Bane, E; Shutske, K; Burke, W, Managing incidental genomic findings: legal obligations of clinicians., Genet Med, vol. 15 no. 8 (August, 2013), pp. 624-629 [doi]  [abs].
  64. Haga, SB; Rosanbalm, KD; Boles, L; Tindall, GM; Livingston, TM; O'Daniel, JM, Promoting public awareness and engagement in genome sciences., J Genet Couns, vol. 22 no. 4 (August, 2013), pp. 508-516 [23435715], [doi]  [abs].
  65. Moaddeb, J; Haga, SB, Pharmacogenetic testing: Current Evidence of Clinical Utility., Therapeutic Advances in Drug Safety, vol. 4 no. 4 (August, 2013), pp. 155-169 [24020014], [doi]  [abs].
  66. Haga, SB; Burke, W; Agans, R, Primary-care physicians' access to genetic specialists: an impediment to the routine use of genomic medicine?, Genet Med, vol. 15 no. 7 (July, 2013), pp. 513-514 [23306802], [doi] .
  67. Mills, R; Haga, SB, Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists., Pharmacogenomics, vol. 14 no. 8 (June, 2013), pp. 957-968 [23746189], [doi]  [abs].
  68. Haga, SB; Barry, WT; Mills, R; Ginsburg, GS; Svetkey, L; Sullivan, J; Willard, HF, Public knowledge of and attitudes toward genetics and genetic testing., Genet Test Mol Biomarkers, vol. 17 no. 4 (April, 2013), pp. 327-335 [23406207], [doi]  [abs].
  69. Haga, SB; Burke, W; Ginsburg, GS; Mills, R; Agans, R, Primary care physicians' knowledge of and experience with pharmacogenetic testing, Obstetrical & Gynecological Survey, vol. 68 no. 2 (February, 2013), pp. 91-93, Ovid Technologies (Wolters Kluwer Health) [doi] .
  70. Haga, SB; Zhao, JQ, Stakeholder views on returning research results., Advances in Genetics, vol. 84 (2013), pp. 41-81 [24262096], [doi]  [abs].
  71. Mills, R; Voora, D; Peyser, B; Haga, SB, Delivering pharmacogenetic testing in a primary care setting., Pharmacogenomics and Personalized Medicine, vol. 6 (2013), pp. 105-112 [24101877], [doi]  [abs].
  72. Hresko, A; Haga, SB, Insurance coverage policies for personalized medicine., Journal of Personalized Medicine, vol. 2 no. 4 (October, 2012), pp. 201-216 [doi]  [abs].
  73. Haga, SB; Burke, W; Ginsburg, GS; Mills, R; Agans, R, Primary care physicians' knowledge of and experience with pharmacogenetic testing., Clin Genet, vol. 82 no. 4 (October, 2012), pp. 388-394 [22698141], [doi]  [abs].
  74. Mills, RA; Haga, SB; Ginsburg, GS, Genetic testing: clinical and personal utility., The Virtual Mentor : Vm, vol. 14 no. 8 (August, 2012), pp. 604-609 [23351313], [doi] .
  75. Haga, SB; O'Daniel, JM; Tindall, GM; Mills, R; Lipkus, IM; Agans, R, Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing., Clin Genet, vol. 82 no. 2 (August, 2012), pp. 115-120 [22283474], [doi]  [abs].
  76. Haga, SB; O'Daniel, JM; Tindall, GM; Mills, R; Lipkus, I; Agans, R, Response to Newman et al, Clinical Genetics, vol. 82 no. 2 (August, 2012), pp. 203 [doi] .
  77. Kraus, WE; Haga, SB; McLeod, HL; Staples, J; Ginsburg, GS, Conference Scene: Is personalized medicine ready for prime time?, Per Med, vol. 9 no. 5 (July, 2012), pp. 475-478 [doi]  [abs].
  78. Haga, SB; O'Daniel, JM; Tindall, GM; Lipkus, IR; Agans, R, Survey of US public attitudes toward pharmacogenetic testing., Pharmacogenomics J, vol. 12 no. 3 (June, 2012), pp. 197-204 [21321582], [doi]  [abs].
  79. Haga, SB; Tindall, G; O'Daniel, JM, Public perspectives about pharmacogenetic testing and managing ancillary findings., Genet Test Mol Biomarkers, vol. 16 no. 3 (March, 2012), pp. 193-197 [22047505], [doi]  [abs].
  80. O'Daniel, JM; Rosanbalm, KD; Boles, L; Tindall, GM; Livingston, TM; Haga, SB, Enhancing geneticists' perspectives of the public through community engagement., Genet Med, vol. 14 no. 2 (February, 2012), pp. 243-249 [22241095], [doi]  [abs].
  81. Cho, AH; Killeya-Jones, LA; O'Daniel, JM; Kawamoto, K; Gallagher, P; Haga, S; Lucas, JE; Trujillo, GM; Joy, SV; Ginsburg, GS, Effect of genetic testing for risk of type 2 diabetes mellitus on health behaviors and outcomes: study rationale, development and design., Bmc Health Services Research, vol. 12 (January, 2012), pp. 16 [22257365], [doi]  [abs].
  82. Haga, SB; Tindall, G; O'Daniel, JM, Professional perspectives about pharmacogenetic testing and managing ancillary findings., Genet Test Mol Biomarkers, vol. 16 no. 1 (January, 2012), pp. 21-24 [21770772], [doi]  [abs].
  83. Kanakamedala, P; Haga, SB, Characterization of clinical study populations by race and ethnicity in biomedical literature., Ethnicity & Disease, vol. 22 no. 1 (2012), pp. 96-101 [22774316]  [abs].
  84. Haga, SB; Kawamoto, K; Agans, R; Ginsburg, GS, Consideration of patient preferences and challenges in storage and access of pharmacogenetic test results., Genet Med, vol. 13 no. 10 (October, 2011), pp. 887-890 [21673581], [doi]  [abs].
  85. Haga, SB; O'Daniel, JM; Tindall, GM; Lipkus, IR; Agans, R, Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions., Genet Med, vol. 13 no. 8 (August, 2011), pp. 723-728 [21633294], [doi]  [abs].
  86. Haga, SB; Carrig, MM; O'Daniel, JM; Orlando, LA; Killeya-Jones, LA; Ginsburg, GS; Cho, A, Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profiling., J Gen Intern Med, vol. 26 no. 8 (August, 2011), pp. 834-840 [21311998], [doi]  [abs].
  87. Haga, SB; Burke, W, Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests., Clinical Pharmacology and Therapeutics, vol. 90 no. 1 (July, 2011), pp. 25-27 [21691271], [doi]  [abs].
  88. Haga, SB; O'Daniel, J, Public perspectives regarding data-sharing practices in genomics research., Public Health Genomics, vol. 14 no. 6 (2011), pp. 319-324 [21430368], [doi]  [abs].
  89. O'Daniel, J; Haga, SB, Public perspectives on returning genetics and genomics research results., Public Health Genomics, vol. 14 no. 6 (2011), pp. 346-355 [21555865], [doi]  [abs].
  90. Heaney, C; Tindall, G; Lucas, J; Haga, SB, Researcher practices on returning genetic research results., Genet Test Mol Biomarkers, vol. 14 no. 6 (December, 2010), pp. 821-827 [20939736], [doi]  [abs].
  91. Surh, LC; Pacanowski, MA; Haga, SB; Hobbs, S; Lesko, LJ; Gottlieb, S; Papaluca-Amati, M; Patterson, SD; Hughes, AR; Kim, M-J; Close, SL; Mosteller, M; Zineh, I; Dechairo, B; Cohen, NA, Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs., Pharmacogenomics, vol. 11 no. 12 (December, 2010), pp. 1637-1647 [doi]  [abs].
  92. Haga, SB, Analysis of educational materials and destruction/opt-out initiatives for storage and use of residual newborn screening samples., Genet Test Mol Biomarkers, vol. 14 no. 5 (October, 2010), pp. 587-592 [20858049], [doi]  [abs].
  93. O'Daniel, JM; Haga, SB; Willard, HF, Considerations for the impact of personal genome information: a study of genomic profiling among genetics and genomics professionals., J Genet Couns, vol. 19 no. 4 (August, 2010), pp. 387-401 [20352309], [doi]  [abs].
  94. Haga, SB, Impact of limited population diversity of genome-wide association studies., Genet Med, vol. 12 no. 2 (February, 2010), pp. 81-84 [20057316], [doi]  [abs].
  95. O'Daniel, J; Lucas, J; Deverka, P; Ermentrout, D; Silvey, G; Lobach, DF; Haga, SB, Factors influencing uptake of pharmacogenetic testing in a diverse patient population., Public Health Genomics, vol. 13 no. 1 (2010), pp. 48-54 [19407441], [doi]  [abs].
  96. Haga, SB; Terry, SF, Ensuring the safe use of genomic medicine in children., Clin Pediatr (Phila), vol. 48 no. 7 (September, 2009), pp. 703-708 [19448129], [doi]  [abs].
  97. Haga, SB, Ethical issues of predictive genetic testing for diabetes., Journal of Diabetes Science and Technology, vol. 3 no. 4 (July, 2009), pp. 781-788 [20144329], [doi]  [abs].
  98. Haga, SB; Warner, LR; O'Daniel, J, The potential of a placebo/nocebo effect in pharmacogenetics., Public Health Genomics, vol. 12 no. 3 (2009), pp. 158-162 [19204418], [doi]  [abs].
  99. Haga, SB; Burke, W, Pharmacogenetic testing: not as simple as it seems., Genet Med, vol. 10 no. 6 (June, 2008), pp. 391-395 [18496219], [doi]  [abs].
  100. Haga, SB; Willard, HF, Letting the genome out of the bottle., The New England Journal of Medicine, vol. 358 no. 20 (May, 2008), pp. 2184 [doi] .
  101. Haga, SB; Beskow, LM, Ethical, legal, and social implications of biobanks for genetics research., Advances in Genetics, vol. 60 (2008), pp. 505-544 [18358331], [doi]  [abs].
  102. Silvey, GM; Haga, SB; O'Daniel, JM; Deverka, P; Ermentrout, DM; Anstrom, KJ; Lobach, DF, Determining user preferences between touch and pen data entry methods in the Tablet PC computing environment., Amia ... Annual Symposium Proceedings. Amia Symposium (October, 2007), pp. 1115 [18694212]  [abs].
  103. Haga, SB; Thummel, KE; Burke, W, Adding pharmacogenetics information to drug labels: lessons learned., Pharmacogenetics and Genomics, vol. 16 no. 12 (December, 2006), pp. 847-854 [17108808], [doi]  [abs].
  104. Haga, SB; Willard, HF, Defining the spectrum of genome policy., Nature Reviews. Genetics, vol. 7 no. 12 (December, 2006), pp. 966-972 [17139328], [doi]  [abs].
  105. Haga, SB, Genomics-based labeling and attribution: a case for integrating social sciences into personalized medicine research., Per Med, vol. 3 no. 3 (August, 2006), pp. 317-323 [doi]  [abs].
  106. Haga, SB; Ginsburg, GS, Prescribing BiDil: is it black and white?, J Am Coll Cardiol, vol. 48 no. 1 (July, 2006), pp. 12-14 [16814642], [doi]  [abs].
  107. Haga, SB, Teaching resources for genetics., Nature Reviews. Genetics, vol. 7 no. 3 (March, 2006), pp. 223-229 [16462854], [doi]  [abs].
  108. Ginsburg, GS; Haga, SB, Translating genomic biomarkers into clinically useful diagnostics., Expert Rev Mol Diagn, vol. 6 no. 2 (March, 2006), pp. 179-191 [16512778], [doi]  [abs].
  109. Rich, EC; Burke, W; Heaton, CJ; Haga, S; Pinsky, L; Short, MP; Acheson, L, Erratum: Reconsidering the family history in primary care (Journal of General Internal Medicine (2004) 19 (273-280)), Journal of General Internal Medicine, vol. 20 no. 3 (March, 2005), pp. 315 [doi] .
  110. Haga, SB, Embracing our duty, American Journal of Human Genetics, vol. 76 no. 4 (January, 2005), pp. 547, Elsevier BV [doi] .
  111. Haga, SB; Burke, W, Using pharmacogenetics to improve drug safety and efficacy., Jama, vol. 291 no. 23 (June, 2004), pp. 2869-2871 [doi] .
  112. Rich, EC; Burke, W; Heaton, CJ; Haga, S; Pinsky, L; Short, MP; Acheson, L, Reconsidering the family history in primary care., Journal of General Internal Medicine, vol. 19 no. 3 (March, 2004), pp. 273-280, Springer Nature [doi]  [abs].
  113. Haga, SB; Khoury, MJ; Burke, W, Genomic profiling to promote a healthy lifestyle: not ready for prime time., Nature Genetics, vol. 34 no. 4 (August, 2003), pp. 347-350 [doi]  [abs].
  114. Haga, SB; Venter, JC, Genetics. FDA races in wrong direction., Science, vol. 301 no. 5632 (July, 2003), pp. 466 [doi]  [abs].
  115. Haga, SB; Boughman, JA, The genetics workforce and workload., Genetics in Medicine : Official Journal of the American College of Medical Genetics, vol. 5 no. 1 (January, 2003), pp. 55-57 [doi] .
  116. Chase, MB; Fu, S; Haga, SB; Davenport, G; Stevenson, H; Do, K; Morgan, D; Mah, AL; Berg, PE, BP1, a homeodomain-containing isoform of DLX4, represses the beta-globin gene., Molecular and Cellular Biology, vol. 22 no. 8 (April, 2002), pp. 2505-2514 [doi]  [abs].
  117. Fu, S; Stevenson, H; Strovel, JW; Haga, SB; Stamberg, J; Do, K; Berg, PE, Distinct functions of two isoforms of a homeobox gene, BP1 and DLX7, in the regulation of the beta-globin gene., Gene, vol. 278 no. 1-2 (October, 2001), pp. 131-139 [doi]  [abs].
  118. Haga, SB; Fu, S; Karp, JE; Ross, DD; Williams, DM; Hankins, WD; Behm, F; Ruscetti, FW; Chang, M; Smith, BD; Becton, D; Raimondi, SC; Berg, PE, BP1, a new homeobox gene, is frequently expressed in acute leukemias., Leukemia, vol. 14 no. 11 (November, 2000), pp. 1867-1875 [doi]  [abs].
  119. Chase, MB; Haga, SB; Hankins, WD; Williams, DM; Bi, Z; Strovel, JW; Obriecht, C; Berg, PE, Binding of HMG-I(Y) elicits structural changes in a silencer of the human beta-globin gene., American Journal of Hematology, vol. 60 no. 1 (January, 1999), pp. 27-35, WILEY [doi]  [abs].

Chapters in Books

  1. Ginsburg, GS; Haga, SB, Foundations and application of precision medicine, in Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics: Foundations (January, 2018), pp. 21-45 [doi]  [abs].
  2. Haga, SB, Precision Medicine and Challenges in Research and Clinical Implementation, in Principles of Gender-Specific Medicine: Gender in the Genomic Era: Third Edition (May, 2017), pp. 717-732, Elsevier [doi]  [abs].
  3. Haga, SB, Overview of Policy, Ethical, and Social Considerations in Genomic and Personalized Medicine, in Genomic and Precision Medicine: Primary Care: Third Edition (March, 2017), pp. 19-43, Elsevier [doi]  [abs].
  4. Haga, SB, Overview of Policy, Ethical and Social Considerations in Genomic and Personalized Medicine, in Genomic and Personalized Medicine, vol. 1 (August, 2013), pp. 392-404 [doi] .
  5. Cho, A; Vorderstrasse, A; Suchindran, S; Lucas, J; Scott, WM; Bembe, M; Baker, D; Haga, SB; Orlando, L; Trujillo, GM; Joy, SV; Ginsburg, GS, T2D Genetic Risk Counseling & Testing in Primary Care, Diabetes, vol. 62 (July, 2013), pp. A196-A196, AMER DIABETES ASSOC .
  6. Haga, SB, Genome Policy Considerations for Genomic Medicine, in Essentials of Genomic and Personalized Medicine (December, 2010), pp. 209-222, Elsevier [doi]  [abs].
  7. Haga, SB, From Sequence to Genomic Medicine: Genome Policy Considerations, in Genomic and Personalized Medicine, Two-Vol Set (December, 2009), pp. 387-400, Elsevier [doi] .